Level Four Advisory Services
IBRX icon

Level Four Advisory Services’s ImmunityBio IBRX Stock Holding History

Level Four Advisory Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$111K Buy
+11,738
New +$93.8K ﹤0.01% 926

Other funds holding IBRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Level Four Advisory Services's IBRX Position: Q3 2026 in Review

Level Four Advisory Services opened a new position in ImmunityBio (IBRX) in Q3 2026: 11,738 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #926 among its holdings.

321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Level Four Advisory Services held 11,738 shares of ImmunityBio worth $111K as of Q3 2026.
  • ImmunityBio was a new Level Four Advisory Services position in Q3 2026.
  • ImmunityBio made up ﹤0.01% of Level Four Advisory Services's portfolio in Q3 2026, its #926 holding.
  • 321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Level Four Advisory Services's 13F filing for Q3 2026, filed 6 Nov 2026.